130 related articles for article (PubMed ID: 21047207)
1. Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
Pallet N; Legendre C
Pharmacogenomics; 2010 Oct; 11(10):1491-501. PubMed ID: 21047207
[TBL] [Abstract][Full Text] [Related]
2. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts.
Liptak P; Ivanyi B
Nat Clin Pract Nephrol; 2006 Jul; 2(7):398-404; quiz following 404. PubMed ID: 16932468
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring of calcineurin inhibitors induced-nephrotoxicity].
Kamar N; Rostaing L
Nephrol Ther; 2008 Jun; 4 Suppl 1():S13-S17. PubMed ID: 18703392
[TBL] [Abstract][Full Text] [Related]
4. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
Gaston RS
Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
[TBL] [Abstract][Full Text] [Related]
5. Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.
Pallet N; Djamali A; Legendre C
Pharmacol Res; 2011 Jul; 64(1):25-30. PubMed ID: 21473913
[TBL] [Abstract][Full Text] [Related]
6. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Bai JP; Lesko LJ; Burckart GJ
Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
[TBL] [Abstract][Full Text] [Related]
7. [Calcineurin inhibitor nephrotoxicity in renal allografts].
Takeda A; Morozumi K
Nihon Jinzo Gakkai Shi; 2011; 53(4):610-4. PubMed ID: 21688481
[No Abstract] [Full Text] [Related]
8. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
Hesselink DA; Bouamar R; van Gelder T
Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
[TBL] [Abstract][Full Text] [Related]
9. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
Coates PT;
Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
[No Abstract] [Full Text] [Related]
10. Is arteriolar vacuolization a predictor of calcineurin inhibitor nephrotoxicity?
Horike K; Takeda A; Yamaguchi Y; Ogiyama Y; Yamauchi Y; Murata M; Kawaguchi T; Suzuki T; Otsuka Y; Inaguma D; Goto N; Watarai Y; Uchida K; Morozumi K
Clin Transplant; 2011 Jul; 25 Suppl 23():23-7. PubMed ID: 21623910
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells.
González-Guerrero C; Ocaña-Salceda C; Berzal S; Carrasco S; Fernández-Fernández B; Cannata-Ortiz P; Egido J; Ortiz A; Ramos AM
Toxicol Appl Pharmacol; 2013 Nov; 272(3):825-41. PubMed ID: 23958496
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor nephrotoxicity.
Naesens M; Kuypers DR; Sarwal M
Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
[TBL] [Abstract][Full Text] [Related]
14. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.
Esposito C; Foschi A; Parrilla B; Cornacchia F; Fasoli G; Plati AR; De Mauri A; Mazzullo T; Scudellaro R; Dal Canton A
Transplant Proc; 2004 Apr; 36(3):695-7. PubMed ID: 15110634
[TBL] [Abstract][Full Text] [Related]
15. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
16. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
Issa N; Kukla A; Ibrahim HN
Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
19. [Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors].
Snanoudj R; Rabant M; Royal V; Pallet N; Noël LH; Legendre C
Nephrol Ther; 2009 Dec; 5 Suppl 6():S365-70. PubMed ID: 20129447
[TBL] [Abstract][Full Text] [Related]
20. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
Metalidis C; Lerut E; Naesens M; Kuypers DR
Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
